[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,418,256
  • Shares Outstanding, K 102,955
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,843 M
  • EBITDA $ 4,387 M
  • 60-Month Beta 0.22
  • Price/Sales 5.79
  • Price/Cash Flow 19.14
  • Price/Book 2.61

Options Overview Details

View History
  • Implied Volatility 26.29% (+0.08%)
  • Historical Volatility 28.57%
  • IV Percentile 2%
  • IV Rank 1.40%
  • IV High 49.01% on 10/10/25
  • IV Low 25.96% on 08/14/26
  • Expected Move (DTE 2) 13.35 (1.65%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 1,083
  • Volume Avg (30-Day) 2,052
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 39,489
  • Open Int (30-Day) 40,161
  • Expected Range 796.90 to 823.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $12.89
  • Number of Estimates 6
  • High Estimate $15.06
  • Low Estimate $9.58
  • Prior Year $9.63
  • Growth Rate Est. (year over year) +33.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
637.80 +27.04%
on 07/23/26
821.02 -1.31%
on 08/18/26
+133.55 (+19.74%)
since 07/17/26
3-Month
591.52 +36.98%
on 06/02/26
821.02 -1.31%
on 08/18/26
+180.56 (+28.67%)
since 05/18/26
52-Week
541.00 +49.77%
on 10/13/25
821.11 -1.32%
on 01/09/26
+236.33 (+41.18%)
since 08/18/25

Most Recent Stories

More News
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

NEW YORK , Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 810.24 (+0.53%)
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 18, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 810.24 (+0.53%)
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman

SAN FRANCISCO , Aug. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 810.24 (+0.53%)
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint,...

REGN : 810.24 (+0.53%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  ...

REGN : 810.24 (+0.53%)
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 12, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 810.24 (+0.53%)
REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline

NEW YORK , Aug. 11, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).

REGN : 810.24 (+0.53%)
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO , Aug. 10, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in  Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit...

REGN : 810.24 (+0.53%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  ...

REGN : 810.24 (+0.53%)
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

SAN FRANCISCO , Aug. 6, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN)  that a securities class action lawsuit has been filed...

REGN : 810.24 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 833.95
2nd Resistance Point 827.49
1st Resistance Point 818.86
Last Price 810.24
1st Support Level 803.77
2nd Support Level 797.31
3rd Support Level 788.68

See More

52-Week High 821.11
Last Price 810.24
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.